

Amendments to the Claims

Please amend claims 22 and 23, and add claims 35-45. Please cancel claims 1-21 and 24-34 without prejudice or disclaimer. Following this amendment claims 22-23 and 35-45 will be pending.

Claims 1-21. (cancelled).

D2
Claims 22. (Currently Amended): A method for enhancing the effectiveness of a nicotine replacement therapy consisting essentially of: comprising contemporaneously administering to an individual in need of nicotine replacement therapy a therapeutically effective amount of (a) nicotine and (b) one or more substances selected from the group consisting of (i) substances which inhibit CYP2A activity; (ii) substances which inhibit transcription, and/or translation of the gene encoding CYP2A; and (iii) substances which delete all or a portion of the gene encoding CYP2A; and
→ optionally (c) one or more substances selected from the group consisting of substances which inhibit CYP2B6 activity, substances which inhibit transcription and/or translation of the gene encoding CYP2B6, or a combination thereof;
wherein (a), (b), and (c) if present, are administered contemporaneously.

either there or not -

D3
Claim 23. (Currently Amended): A method according to claim 22 wherein said substance which inhibits CYP2A6 and is methoxsalen, psoralen, tranlycypromine, pilocarpine, coumarin, chromone, esculetin, phenelzine, paroxetine, selegiline, or pargyline.

Claims 24-34 (Cancelled).

Rule 1.126 - 37
D4
Claim 35. (New): The method according to claim 22, wherein the substances of group (c) are selected from phenylethyl amines, diphenylbarbiturates, diethyl substituted barbiturates, and hydantoins.

38
m
Claim 36. (New): A method for enhancing the effectiveness of a nicotine

replacement therapy comprising administering to an individual in need of nicotine replacement therapy a therapeutically effective amount of nicotine and one or more substances which inhibit CYP2A activity;

wherein the substances which inhibits CYP2A activity is selected from methoxsalen, psoralen, tranlycypromine, coumarin, chromone, esculetin, phenelzine, paroxetine, selegiline and pargyline, *Hypericum* and extracts thereof, *Cichorium intybus* and extracts thereof, and *Bougainvillra spectabilis* and extracts thereof.

31
Claim 37. (New): A method for enhancing the effectiveness of a nicotine replacement therapy comprising: administering to an individual in need of nicotine replacement therapy a therapeutically effective amount of nicotine and one or more substances which inhibit transcription, and/or translation of the gene encoding CYP2A.

40
Claim 38. (New): A method for enhancing the effectiveness of a nicotine replacement therapy comprising: administering to an individual in need of nicotine replacement therapy a therapeutically effective amount of nicotine and one or more substances which delete all or a portion of the gene encoding CYP2A.

41
Claim 39. (New): A method according to claims 36, wherein methoxsalen is administered in an amount from 0.1 mg to 50 mg

42
Claim 40. (New) A method according to claim 36, wherein coumarin is administered in an amount from 1 mg to 1000 mg.

43
Claim 41. (New) A method according to claim 36, wherein tranlycypromine is administered in an amount from 0.1 mg to 80 mg.

44
Claim 42. (New): A method for enhancing the effectiveness of a nicotine replacement therapy comprising administering to an individual in need of nicotine replacement therapy a therapeutically effective amount of nicotine and methoxsalen.

43
Claim 43. (New): A method for enhancing the effectiveness of a nicotine replacement therapy comprising administering to an individual in need of nicotine replacement therapy a therapeutically effective amount of nicotine and coumarin

44
Claim 44. (New): A method for enhancing the effectiveness of a nicotine replacement therapy comprising administering to an individual in need of nicotine replacement therapy a therapeutically effective amount of nicotine and tranlycypromine.

45
Claim 45. (New): A method for enhancing the effectiveness of a nicotine replacement therapy consisting essentially of: administering to an individual in need of nicotine replacement therapy a therapeutically effective amount of (a) nicotine and (b) one or more substances selected from the group consisting of (i) substances which inhibit CYP2A activity; (ii) substances which inhibit transcription, and/or translation of the gene encoding CYP2A; and (iii) substances which delete all or a portion of the gene encoding CYP2A;

wherein (a) and (b) are administered contemporaneously.